PATENT CLAIM ANALYSIS

Application Number: 16167371
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "108000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Claim (Index 24):
The method of  claim 7 , wherein about 100 mg of the neridronic acid is intravenously administered 4 times.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 97.0
- Lexical Diversity: 1.26667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15840066', '15647140', '15710759', '15357932', '15716334']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8580377769457529
- 35 USC 102 Novelty (BERT): 0.6560834391962808
- Combined Prediction Score: 0.8378423431708057
- Mean Citation Score: 611.1782519999998
- Max Citation Score: 618.2427
- Similarity Product: 482.57910665790433

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test